KTRA
Kintara Therapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 0.2356
- Prev close
- 0.2154
- Mkt cap
- 11.99M
- Vol
- 3.55M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2049
- High
- 0.2356
- Forward P/E
- -0.57
- Beta
- 0.81
- Short ratio
- 1.14
- Inst. own
- 1.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2024
- 50-d avg
- 6.67
- 200-d avg
- 6.02
- 1y target
- 0.00
Key statistics
- Market cap
- 11.99M
- Enterprise value
- 17.33M
- Trailing P/E
- 0.00
- Forward P/E
- -0.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -11.20
- Beta
- 0.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.18M
- Total cash
- 4.91M
- Total debt
- 0
- Return on equity
- -370.77%
- Shares outstanding
- 55.66M
- Short % of float
- 9.81%
- 50-day average
- 6.67
- 200-day average
- 6.02
Analyst view
Consensus: hold
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Sep 18, 2023 | Jun 1, 2023 | -0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 14, 2023 | Maxim Group | up | Hold | Buy |
About Kintara Therapeutics, Inc.
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kintara.com
News
- Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
- Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
- Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
- Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
- Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
- Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
- Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
- Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
- Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
Your note
Sign in to keep a note on KTRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HOFFMAN ROBERT E | Chief Executive Officer | Stock Award(Grant) | May 31, 2023 | 68,902 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.62% | 343,912 | 74.08K | Jun 29, 2024 |
| Susquehanna International Group, LLP | 0.20% | 109,255 | 23.53K | Jun 29, 2024 |
| Xtx Topco Ltd | 0.13% | 74,115 | 15.96K | Jun 29, 2024 |
| Jane Street Group, LLC | 0.09% | 47,874 | 10.31K | Jun 29, 2024 |
| Baader Bank Aktiengesellschaft | 0.08% | 42,670 | 9.19K | Jun 29, 2024 |
| Level Four Advisory Services, LLC | 0.08% | 44,642 | 9.62K | Jun 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 303,025 | 65.27K | Aug 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 54,121 | 11.66K | Aug 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 30,458 | 6.56K | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.02% | 12,455 | 2.68K | Jun 29, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 9,778 | 2.11K | Aug 30, 2024 |